ClearPoint Neuro Q1 revenue $12.1M (+43% YoY); guides FY2026 $52-56M

ClearPoint Neuro, Inc.

2026-Q1 EPS reported -$0.32 vs consensus -$0.27 ▼ miss (-20.7%)

Record Q1 revenue of $12.1M; organic device growth 25% YoY; gross margin expanded to 64% from 60%.
Neurosurgery navigation revenue surged 80% to $5.9M, driven by IRRA flow and 3.0 software adoption.
Biologics & drug delivery revenue stable at $4.8M; over 60 active biopharma partners enrolled.
Cash and equivalents $35.6M at Mar 31, 2026; expects cash burn to reduce in H2 2026 from cost synergies.
FDA cleared Velocity Alpha drill used in first clinical procedure; Health Canada MDL license obtained.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ClearPoint Neuro, Inc. reported first fiscal quarter ended March 31, 2026 results: revenue $12.1 million. Guidance reaffirmed.

Period: first fiscal quarter ended March 31, 2026
Revenue: $12.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Highlights • Reported first quarter revenue of $12.1 million, including $2.3 million of IRRA flow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025; • The activated

View on SEC.gov

Browse all earnings releases →

ClearPoint Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-221596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.